International Clinical Trial: A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjogren's Syndrome

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07727486) titled 'A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjogren's Syndrome' on July 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Condition: Primary Sjogren's Syndrome

Intervention: Drug: ICP-488 Tablets

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 2026

Target Sample Size: 240

Countries of Recruitment: China

To ...